Advocacy at a Glance STEVEN GROSSMAN 7/14/17 Advocacy at a Glance STEVEN GROSSMAN 7/14/17 More Good Progress; Still No Certainties Read More Advocacy at a Glance STEVEN GROSSMAN 7/14/17 Advocacy at a Glance STEVEN GROSSMAN 7/14/17 FDA Starts FY 19 Budget Planning Long Before FY 18 Process is Completed and more Read More Analysis and Commentary STEVEN GROSSMAN 6/30/17 Analysis and Commentary STEVEN GROSSMAN 6/30/17 Happier ... But Not Out of the Woods by Any Means Read More Advocacy at a Glance STEVEN GROSSMAN 6/30/17 Advocacy at a Glance STEVEN GROSSMAN 6/30/17 User fees in House Appropriations Bill Consistent With FDARA Numbers and more Read More STEVEN GROSSMAN 6/29/17 STEVEN GROSSMAN 6/29/17 Alliance Applauds House Ag/FDA Appropriations Subcommittee Read More Analysis and Commentary STEVEN GROSSMAN 6/23/17 Analysis and Commentary STEVEN GROSSMAN 6/23/17 Fuzzy Math and New Score (but Not on Goal) Read More Advocacy at a Glance STEVEN GROSSMAN 6/23/17 Advocacy at a Glance STEVEN GROSSMAN 6/23/17 CBO Score on Senate FDARA Bill Leads to Confusion About Unfunded Mandates and more Read More Analysis and Commentary STEVEN GROSSMAN 6/16/17 Analysis and Commentary STEVEN GROSSMAN 6/16/17 From Fantasy to a Potential Reality ... Maybe? Read More Advocacy at a Glance STEVEN GROSSMAN 6/16/17 Advocacy at a Glance STEVEN GROSSMAN 6/16/17 What FDA Deputy Commissioner Ostroff Said About Food Read More Analysis and Commentary STEVEN GROSSMAN 6/9/17 Analysis and Commentary STEVEN GROSSMAN 6/9/17 The Realities of the FY 18 Budget; Some Qs&As Read More Advocacy at a Glance STEVEN GROSSMAN 6/9/17 Advocacy at a Glance STEVEN GROSSMAN 6/9/17 Questions About FDA and the Federal Budget and more Read More Analysis and Commentary STEVEN GROSSMAN 5/31/17 Analysis and Commentary STEVEN GROSSMAN 5/31/17 How the Federal Budget Applies to the FDA -- A Refresher for FY 18 Read More Advocacy at a Glance STEVEN GROSSMAN 5/31/17 Advocacy at a Glance STEVEN GROSSMAN 5/31/17 FDA In the Context of the Federal Budget and more Read More Analysis and Commentary STEVEN GROSSMAN 5/26/17 Analysis and Commentary STEVEN GROSSMAN 5/26/17 The Good News; the Bad News; and What's Next? Read More Advocacy at a Glance STEVEN GROSSMAN 5/26/17 Advocacy at a Glance STEVEN GROSSMAN 5/26/17 New FDA Commissioner Testifies and more Read More STEVEN GROSSMAN 5/23/17 STEVEN GROSSMAN 5/23/17 President Trump's FY 18 Budget Request Threatens FDA's Mission Read More Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 How a 6% Budget Increase Can Actually Be a 45% Decrease Read More Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 New FDA Commissioner Scott Gottlieb Read More Analysis and Commentary STEVEN GROSSMAN 5/12/17 Analysis and Commentary STEVEN GROSSMAN 5/12/17 Proposed FDA FY 18 Budget Swap a Non-Starter Read More Advocacy at a Glance STEVEN GROSSMAN 5/12/17 Advocacy at a Glance STEVEN GROSSMAN 5/12/17 President’s Full Budget Release Set for May 23 and more Read More Newer Posts Older Posts
Advocacy at a Glance STEVEN GROSSMAN 7/14/17 Advocacy at a Glance STEVEN GROSSMAN 7/14/17 More Good Progress; Still No Certainties Read More
Advocacy at a Glance STEVEN GROSSMAN 7/14/17 Advocacy at a Glance STEVEN GROSSMAN 7/14/17 FDA Starts FY 19 Budget Planning Long Before FY 18 Process is Completed and more Read More
Analysis and Commentary STEVEN GROSSMAN 6/30/17 Analysis and Commentary STEVEN GROSSMAN 6/30/17 Happier ... But Not Out of the Woods by Any Means Read More
Advocacy at a Glance STEVEN GROSSMAN 6/30/17 Advocacy at a Glance STEVEN GROSSMAN 6/30/17 User fees in House Appropriations Bill Consistent With FDARA Numbers and more Read More
STEVEN GROSSMAN 6/29/17 STEVEN GROSSMAN 6/29/17 Alliance Applauds House Ag/FDA Appropriations Subcommittee Read More
Analysis and Commentary STEVEN GROSSMAN 6/23/17 Analysis and Commentary STEVEN GROSSMAN 6/23/17 Fuzzy Math and New Score (but Not on Goal) Read More
Advocacy at a Glance STEVEN GROSSMAN 6/23/17 Advocacy at a Glance STEVEN GROSSMAN 6/23/17 CBO Score on Senate FDARA Bill Leads to Confusion About Unfunded Mandates and more Read More
Analysis and Commentary STEVEN GROSSMAN 6/16/17 Analysis and Commentary STEVEN GROSSMAN 6/16/17 From Fantasy to a Potential Reality ... Maybe? Read More
Advocacy at a Glance STEVEN GROSSMAN 6/16/17 Advocacy at a Glance STEVEN GROSSMAN 6/16/17 What FDA Deputy Commissioner Ostroff Said About Food Read More
Analysis and Commentary STEVEN GROSSMAN 6/9/17 Analysis and Commentary STEVEN GROSSMAN 6/9/17 The Realities of the FY 18 Budget; Some Qs&As Read More
Advocacy at a Glance STEVEN GROSSMAN 6/9/17 Advocacy at a Glance STEVEN GROSSMAN 6/9/17 Questions About FDA and the Federal Budget and more Read More
Analysis and Commentary STEVEN GROSSMAN 5/31/17 Analysis and Commentary STEVEN GROSSMAN 5/31/17 How the Federal Budget Applies to the FDA -- A Refresher for FY 18 Read More
Advocacy at a Glance STEVEN GROSSMAN 5/31/17 Advocacy at a Glance STEVEN GROSSMAN 5/31/17 FDA In the Context of the Federal Budget and more Read More
Analysis and Commentary STEVEN GROSSMAN 5/26/17 Analysis and Commentary STEVEN GROSSMAN 5/26/17 The Good News; the Bad News; and What's Next? Read More
Advocacy at a Glance STEVEN GROSSMAN 5/26/17 Advocacy at a Glance STEVEN GROSSMAN 5/26/17 New FDA Commissioner Testifies and more Read More
STEVEN GROSSMAN 5/23/17 STEVEN GROSSMAN 5/23/17 President Trump's FY 18 Budget Request Threatens FDA's Mission Read More
Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 How a 6% Budget Increase Can Actually Be a 45% Decrease Read More
Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 New FDA Commissioner Scott Gottlieb Read More
Analysis and Commentary STEVEN GROSSMAN 5/12/17 Analysis and Commentary STEVEN GROSSMAN 5/12/17 Proposed FDA FY 18 Budget Swap a Non-Starter Read More
Advocacy at a Glance STEVEN GROSSMAN 5/12/17 Advocacy at a Glance STEVEN GROSSMAN 5/12/17 President’s Full Budget Release Set for May 23 and more Read More
